Wechselwirkungen · Pyrukynd
Pyrukynd 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 22
HOS-147916 · Präparat HOS-099782
CYP3A4 inducers The effect of rifampicin (a strong CYP3A4 inducer) on the pharmacokinetics of a single dose of mitapivat was evaluated in a Phase 1 study. Rifampicin decreased mitapivat AUC0-t, AUC∞ and Cmax by 91%, 91% and 77%, respectively. Decreased mitapivat plasma exposures may reduce the efficacy of mitapivat. The concomitant use of CYP3A4 inducers with mitapivat should be avoided (see section 4.4). If concomitant use of a CYP3A4 inducer is unavoidable, patients should be monitored for reduced efficacy of mitapivat. Patients should not exceed the recommended dose of 100 mg twice daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T11:25:00Z · SHA-256 03d501776d0624826818135ad3ead3dbd02ded30f25a5a3920a5a762850351f5 · Passage d73638ab839aa80bcea242654d73c75bc8cf4368a0caac9dece7613c502145c9 · Zeichen 1154–1752 im Abschnitt